HRP20170415T1 - Antagonisti toll-like receptora 3 - Google Patents
Antagonisti toll-like receptora 3 Download PDFInfo
- Publication number
- HRP20170415T1 HRP20170415T1 HRP20170415TT HRP20170415T HRP20170415T1 HR P20170415 T1 HRP20170415 T1 HR P20170415T1 HR P20170415T T HRP20170415T T HR P20170415TT HR P20170415 T HRP20170415 T HR P20170415T HR P20170415 T1 HRP20170415 T1 HR P20170415T1
- Authority
- HR
- Croatia
- Prior art keywords
- isolated antibody
- antibody
- fragment
- inhibits
- fragment according
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- 239000012634 fragment Substances 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 claims 6
- 102000008230 Toll-like receptor 3 Human genes 0.000 claims 5
- 108010060885 Toll-like receptor 3 Proteins 0.000 claims 5
- 230000004968 inflammatory condition Effects 0.000 claims 5
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims 4
- 208000036142 Viral infection Diseases 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 230000009385 viral infection Effects 0.000 claims 4
- 108090001005 Interleukin-6 Proteins 0.000 claims 3
- 230000004071 biological effect Effects 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 238000003571 reporter gene assay Methods 0.000 claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010050685 Cytokine storm Diseases 0.000 claims 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 2
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims 2
- 108010057466 NF-kappa B Proteins 0.000 claims 2
- 102000003945 NF-kappa B Human genes 0.000 claims 2
- 206010035664 Pneumonia Diseases 0.000 claims 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 206010052015 cytokine release syndrome Diseases 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 201000001421 hyperglycemia Diseases 0.000 claims 2
- 206010022000 influenza Diseases 0.000 claims 2
- 230000017306 interleukin-6 production Effects 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000029713 Catastrophic antiphospholipid syndrome Diseases 0.000 claims 1
- 206010009895 Colitis ischaemic Diseases 0.000 claims 1
- 206010056979 Colitis microscopic Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010058838 Enterocolitis infectious Diseases 0.000 claims 1
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 claims 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 206010051606 Necrotising colitis Diseases 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 210000000577 adipose tissue Anatomy 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 230000010085 airway hyperresponsiveness Effects 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000000748 cardiovascular system Anatomy 0.000 claims 1
- 210000000845 cartilage Anatomy 0.000 claims 1
- 208000008609 collagenous colitis Diseases 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000003038 endothelium Anatomy 0.000 claims 1
- 210000000981 epithelium Anatomy 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 210000005003 heart tissue Anatomy 0.000 claims 1
- 230000002440 hepatic effect Effects 0.000 claims 1
- 102000045716 human TLR3 Human genes 0.000 claims 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 1
- 201000008980 hyperinsulinism Diseases 0.000 claims 1
- 208000027139 infectious colitis Diseases 0.000 claims 1
- 230000008595 infiltration Effects 0.000 claims 1
- 238000001764 infiltration Methods 0.000 claims 1
- 208000037797 influenza A Diseases 0.000 claims 1
- 201000008222 ischemic colitis Diseases 0.000 claims 1
- 210000001503 joint Anatomy 0.000 claims 1
- 210000002429 large intestine Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 208000004341 lymphocytic colitis Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 208000004995 necrotizing enterocolitis Diseases 0.000 claims 1
- 210000000440 neutrophil Anatomy 0.000 claims 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 claims 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 210000005222 synovial tissue Anatomy 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000036269 ulceration Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
Claims (10)
1. Izolirano antitijelo ili njegov fragment reaktivan s toll-like receptorom 3 (TLR3), koji sadrži varijabilne regije i teškog lanca i lakog lanca, pri čemu antitijelo obuhvaća:
a. aminokiselinske sekvence teškog lanca CDR 1, 2 i 3 kao što je prikazano u SEK ID Br:s 82, 86 i 84; i
b. aminokiselinske sekvence lakog lanca CDR 1, 2 i 3 kao što je prikazano u SEK ID Br:s 79, 80 i 87.
2. Izolirano antitijelo ili fragment prema zahtjevu 1, koji sadrži varijabilnu regiju teškog lanca SEK ID Br: 216 i varijabilnu regiju lakog lanca SEK ID Br: 41.
3. Izolirano antitijelo ili fragment prema zahtjevu 1 ili zahtjevu 2, koji sadrži teški lanac SEK ID Br: 220 i laki lanac SEK ID Br: 156.
4. Izolirano antitijelo ili fragment prema bilo kojem od patentnih zahtjeva od 1 do 3, naznačeno time da antitijelo ima najmanje jedno od slijedećih svojstava:
a. smanjuje biološku aktivnost humanog TLR3 u in vitro poli(I:C) NF-κB testu reporterskog gena za > 50% pri <1 µg/ml;
b. inhibira> 60% produkciju IL-6 ili CXCL10/IP-10 iz BEAS-2B stanica stimuliranih sa <100 ng /ml poli(I:C) pri <10 µg/mL;
c. inhibira> 50% produkciju IL-6 ili CXCL10/IP-10 iz BEAS-2B stanica stimuliranih sa <100 ng /ml poli(I:C) pri <0.4 µg/ml;
d. inhibira>50% produkciju IL-6 iz NHBE stanica stimuliranih sa 62.5 ng/ml poli(I:C) pri <5 µg/ml;
e. inhibira>50% produkciju IL-6 iz NHBE stanica stimuliranih sa 62.5 ng/ml poli(I:C) pri <1 µg/ml;
f. inhibira> 20% poli (I: C) induciranu produkciju IFN-γ IL-6 ili IL-12 pomoću PBMC stanica pri<1 µg/ml;
g. inhibira biološku aktivnost cynomologus TLR3 u in vitro NF-kB testu reporterskog gena sa IC50 <10 µg/ml; ili
h. inhibira cynomologus biološku aktivnost TLR3 u in vitro ISRE testu reporterskog gena sa IC50 <5 µg/ml.
5. Izolirano antitijelo ili fragment prema bilo kojem od prethodnog
a. antitijelo je potpuno humano;
b. antitijelo ili fragment je humano-adaptirano;
c. antitijelo je konjugirano s polietilen glikolom; ili
d. njegova Fc domena obuhvaća mutacije S229P, P235A ili L236A.
6. Izolirano antitijelo ili fragment prema bilo kojem od prethodnih zahtjeva koje ima IgG4 izotip.
7. Farmaceutski sastav koji sadrži izolirano antitijelo ili fragment prema bilo kojem od prethodnih patentnih zahtjeva i farmaceutski prihvatljiv nosač.
8. Izolirano antitijelo ili fragment prema bilo kojem od zahtjeva od 1 do 6 ili farmaceutski sastav prema zahtjevu 7 za upotrebu u terapiji.
9. Izolirano antitijelo ili fragment prema bilo kojem od zahtjeva od 1 do 6 ili farmaceutski sastav prema zahtjevu 7 za upotrebu u postupku liječenja:
a) inflamatornog stanja, pri čemu inflamatorno stanje opciono:
i) pogađa tkivo izabrano iz grupe koja se sastoji od respiratornog trakta, pluća, gastrointestinalnog trakta, tankog crijeva, debelog crijeva, kolona, rektuma, kardiovaskularnog sistema, srčanog tkiva, krvnih sudova, zglobova, kosti i sinovijalnog tkiva, hrskavice, epitela, endotela, hepatičnog ili adipoznog tkiva;
ii) je povezano sa povećanom infiltracijom neutrofila u tkivu posredovanom od TLR3;
iii) je stanje upale pluća, opciono:
I) astma ili kronična opstruktivna bolest pluća (COPD);
II) izazvano netipičnom hemofilus influencom; ili
III) hiperesponzivnost disajnih puteva, opciono udružena sa astmom, alergijskim rinitisom, COPD ili cističnom fibrozom;
iv) je inflamatorna bolest crijeva;
v) je povezana sa gastrointestinalnom ulceracijom, opciono infektivnim kolitisom, ishemijskim kolitisom, kolagenoznim ili limfocitnim kolitisom ili nekrotizirajućim enterokolitisom; ili
vi) je autoimuna bolest, opciono reumatoidna
b) dijabetes tipa II;
c) hiperglikemija; ili
d) hiperinsulinemija;
pri čemu se postupak sastoji od administriranja terapeutski efikasne količine izoliranog antitijela ili fragmenta ili farmaceutske kompozicije pacijentu kome je to potrebno tokom vremena dovoljnog za liječenje ili prevenciju inflamatornog stanja, dijabetesa tipa II, hiperglikemije ili rezistentnosti na inzulin.
10. Izolirano antitijelo ili fragment prema bilo kojem od zahtjeva od 1 do 6 ili farmaceutska kompozicija prema zahtjevu 7 za upotrebu u postupku liječenja ili prevencije:
a) sistemskog inflamatornog stanja, opciono citokinske oluje ili hipercitokinemije, sistemskog sindroma inflamatornog odgovora (SIRS), graft versus host bolesti (GVHD), akutnog respiratornog distres sindroma (ARDS), teškog akutnog respiratornog distres sindroma (SARS), katastrofalnog antifosfolipidnog sindroma, teške virusne infekcije, influence, pneumonije, šoka ili sepse; ili
b) virusnih infekcija, opciono influence A virusne infekcije;
pri čemu se postupak sastoji od administriranja terapeutski efikasne količine izoliranog antitijela ili fragmenta ili farmaceutske kompozicije pacijentu kome je to potrebno, tokom vremena dovoljnog za liječenje ili prevenciju sistemskog inflamatornog stanja ili virusne infekcije.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10997408P | 2008-10-31 | 2008-10-31 | |
| US16186009P | 2009-03-20 | 2009-03-20 | |
| US16510009P | 2009-03-31 | 2009-03-31 | |
| US17368609P | 2009-04-29 | 2009-04-29 | |
| EP09824182.1A EP2350304B1 (en) | 2008-10-31 | 2009-10-30 | Toll-like receptor 3 antagonists |
| PCT/US2009/062813 WO2010051470A2 (en) | 2008-10-31 | 2009-10-30 | Toll-like receptor 3 antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170415T1 true HRP20170415T1 (hr) | 2017-05-05 |
Family
ID=42129569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170415TT HRP20170415T1 (hr) | 2008-10-31 | 2017-03-13 | Antagonisti toll-like receptora 3 |
Country Status (33)
| Country | Link |
|---|---|
| US (8) | US8409567B2 (hr) |
| EP (1) | EP2350304B1 (hr) |
| JP (1) | JP5751631B2 (hr) |
| KR (1) | KR101683033B1 (hr) |
| CN (2) | CN102300997B (hr) |
| AU (1) | AU2009308763B2 (hr) |
| BR (1) | BRPI0921696A2 (hr) |
| CA (1) | CA2742014A1 (hr) |
| CL (1) | CL2011000975A1 (hr) |
| CO (1) | CO6362052A2 (hr) |
| CY (1) | CY1118797T1 (hr) |
| DK (1) | DK2350304T3 (hr) |
| EA (2) | EA022832B1 (hr) |
| EC (1) | ECSP11011072A (hr) |
| ES (1) | ES2618567T3 (hr) |
| HK (1) | HK1166105A1 (hr) |
| HR (1) | HRP20170415T1 (hr) |
| HU (1) | HUE031756T2 (hr) |
| IL (1) | IL212545A (hr) |
| LT (1) | LT2350304T (hr) |
| MX (1) | MX2011004635A (hr) |
| MY (1) | MY183144A (hr) |
| NI (1) | NI201100085A (hr) |
| NZ (2) | NZ592542A (hr) |
| PE (1) | PE20110808A1 (hr) |
| PL (1) | PL2350304T3 (hr) |
| PT (1) | PT2350304T (hr) |
| RS (1) | RS55861B1 (hr) |
| SI (1) | SI2350304T1 (hr) |
| SM (1) | SMT201700127B (hr) |
| SV (1) | SV2011003891A (hr) |
| UA (1) | UA109397C2 (hr) |
| WO (1) | WO2010051470A2 (hr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130090457A1 (en) * | 2008-10-31 | 2013-04-11 | Janssen Biotech, Inc. | Toll-Like Receptor 3 Antagonists for the Treatment of Metabolic and Cardiovascular Diseases |
| US8460659B2 (en) | 2008-10-31 | 2013-06-11 | Janssen Biotech, Inc. | Toll-like receptor 3 antagonists for the treatment of metabolic and cardiovascular diseases |
| US8409567B2 (en) | 2008-10-31 | 2013-04-02 | Janssen Biotech, Inc. | Toll-like receptor 3 antagonists |
| HUE028021T2 (en) * | 2009-04-29 | 2016-11-28 | Janssen Biotech Inc | Pen-like receptor antagonists |
| CA2766747C (en) | 2009-07-10 | 2019-04-02 | Innate Pharma | Tlr3 binding agents |
| EP2663329A2 (en) | 2011-01-12 | 2013-11-20 | Innate Pharma | Tlr3 binding agents |
| CA2855955A1 (en) * | 2011-09-12 | 2013-03-21 | Janssen Biotech, Inc. | Toll-like receptor 3 antagonists |
| CN104379603B (zh) | 2012-05-31 | 2017-11-07 | 先天制药公司 | Tlr3结合剂 |
| US10370451B2 (en) * | 2013-04-22 | 2019-08-06 | The University Of Tokyo | Preventive or therapeutic agent for inflammatory disease |
| US9198898B2 (en) | 2013-06-24 | 2015-12-01 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
| US8906951B1 (en) | 2013-06-24 | 2014-12-09 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
| WO2015016282A1 (ja) * | 2013-07-30 | 2015-02-05 | 国立大学法人東京大学 | 放射線誘導性消化管症候群の予防又は治療用医薬組成物 |
| GB201522394D0 (en) * | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibodies |
| KR20180104036A (ko) | 2016-01-22 | 2018-09-19 | 머크 샤프 앤드 돔 코포레이션 | 항-응고 인자 xi 항체 |
| SG10202103120UA (en) | 2016-06-14 | 2021-05-28 | Merck Sharp & Dohme | Anti-coagulation factor xi antibodies |
| WO2018165270A1 (en) * | 2017-03-07 | 2018-09-13 | Newtonoid Technologies, L.L.C. | Modular elongate wall-mounted sensor system and method |
| CN109136231B (zh) * | 2018-09-14 | 2019-08-30 | 苏州大学 | 一种翘嘴鳜tlr3基因及其应用 |
| WO2023235771A2 (en) * | 2022-05-31 | 2023-12-07 | The University Of Chicago | Chemical screen of modulators for vaccine adjuvants |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
| CA2461315A1 (en) * | 2001-10-05 | 2003-04-17 | Coley Pharmaceutical Gmbh | Toll-like receptor 3 signaling agonists and antagonists |
| JP2004016021A (ja) * | 2002-06-12 | 2004-01-22 | Japan Science & Technology Corp | 抗体および阻害剤並びにそれを用いた形質転換方法および形質転換キット |
| JP2007524615A (ja) | 2003-06-20 | 2007-08-30 | コーリー ファーマシューティカル ゲーエムベーハー | 低分子トール様レセプター（ｔｌｒ）アンタゴニスト |
| CA2483732A1 (en) | 2004-09-29 | 2006-03-29 | Ronan Le Goffic | Toll-like receptor 3, its signalling associated molecule trif and their use thereof |
| TWI487535B (zh) * | 2004-11-30 | 2015-06-11 | Centocor Inc | 類鐸受體３（ｔｏｌｌ ｌｉｋｅ ｒｅｃｅｐｔｏｒ３）拮抗劑，方法及用途 |
| SG158098A1 (en) * | 2004-11-30 | 2010-01-29 | Centocor Inc 22 30 74 Date Of | Toll like receptor 3 antagonists, methods and uses |
| DK1945820T3 (da) * | 2005-10-27 | 2013-11-11 | Janssen Biotech Inc | Toll-lignende receptor-3-modulatorer, fremgangsmåder og anvendelser |
| US20100183638A1 (en) * | 2007-03-05 | 2010-07-22 | Gowen Brian B | Restrictive agonist of toll-like receptor 3 (tlr3) |
| US20080299138A1 (en) | 2007-05-25 | 2008-12-04 | Duffy Karen E | Toll-Like Receptor 3 Modulators and Uses Thereof |
| EP2334703B1 (en) | 2008-09-17 | 2015-07-08 | Innate Pharma | Compositions and methods for detecting tlr3 |
| US8895263B2 (en) | 2008-10-02 | 2014-11-25 | Janssen Biotech, Inc. | Methods for suppressing toll-like receptor activity |
| US8409567B2 (en) * | 2008-10-31 | 2013-04-02 | Janssen Biotech, Inc. | Toll-like receptor 3 antagonists |
| US20100188778A1 (en) * | 2009-01-29 | 2010-07-29 | Castagna Joseph T | Disk Drive Assembly Having Flexible Support for Flexible Printed Circuit Board |
| HUE028021T2 (en) | 2009-04-29 | 2016-11-28 | Janssen Biotech Inc | Pen-like receptor antagonists |
| CA2766747C (en) * | 2009-07-10 | 2019-04-02 | Innate Pharma | Tlr3 binding agents |
-
2009
- 2009-10-30 US US12/609,675 patent/US8409567B2/en not_active Expired - Fee Related
- 2009-10-30 NZ NZ592542A patent/NZ592542A/xx not_active IP Right Cessation
- 2009-10-30 EP EP09824182.1A patent/EP2350304B1/en active Active
- 2009-10-30 CN CN200980153815.0A patent/CN102300997B/zh not_active Expired - Fee Related
- 2009-10-30 LT LTEP09824182.1T patent/LT2350304T/lt unknown
- 2009-10-30 EA EA201170636A patent/EA022832B1/ru not_active IP Right Cessation
- 2009-10-30 EA EA201500316A patent/EA201500316A1/ru unknown
- 2009-10-30 AU AU2009308763A patent/AU2009308763B2/en not_active Ceased
- 2009-10-30 CN CN201610006370.5A patent/CN105601742A/zh active Pending
- 2009-10-30 RS RS20170263A patent/RS55861B1/sr unknown
- 2009-10-30 HU HUE09824182A patent/HUE031756T2/en unknown
- 2009-10-30 BR BRPI0921696-0A patent/BRPI0921696A2/pt not_active Application Discontinuation
- 2009-10-30 PE PE2011000964A patent/PE20110808A1/es not_active Application Discontinuation
- 2009-10-30 DK DK09824182.1T patent/DK2350304T3/en active
- 2009-10-30 MX MX2011004635A patent/MX2011004635A/es active IP Right Grant
- 2009-10-30 KR KR1020117012075A patent/KR101683033B1/ko active IP Right Grant
- 2009-10-30 JP JP2011534819A patent/JP5751631B2/ja not_active Expired - Fee Related
- 2009-10-30 SI SI200931604A patent/SI2350304T1/sl unknown
- 2009-10-30 MY MYPI2011001876A patent/MY183144A/en unknown
- 2009-10-30 UA UAA201106797A patent/UA109397C2/uk unknown
- 2009-10-30 NZ NZ603824A patent/NZ603824A/xx not_active IP Right Cessation
- 2009-10-30 PT PT98241821T patent/PT2350304T/pt unknown
- 2009-10-30 PL PL09824182T patent/PL2350304T3/pl unknown
- 2009-10-30 WO PCT/US2009/062813 patent/WO2010051470A2/en active Application Filing
- 2009-10-30 CA CA2742014A patent/CA2742014A1/en not_active Abandoned
- 2009-10-30 ES ES09824182.1T patent/ES2618567T3/es active Active
-
2010
- 2010-04-29 US US12/770,147 patent/US8540986B2/en not_active Expired - Fee Related
-
2011
- 2011-04-28 IL IL212545A patent/IL212545A/en not_active IP Right Cessation
- 2011-04-29 NI NI201100085A patent/NI201100085A/es unknown
- 2011-04-29 CL CL2011000975A patent/CL2011000975A1/es unknown
- 2011-04-30 SV SV2011003891A patent/SV2011003891A/es unknown
- 2011-05-12 CO CO11058446A patent/CO6362052A2/es active IP Right Grant
- 2011-05-23 EC EC2011011072A patent/ECSP11011072A/es unknown
-
2012
- 2012-06-13 HK HK12105768.5A patent/HK1166105A1/zh not_active IP Right Cessation
-
2013
- 2013-01-28 US US13/751,718 patent/US9481731B2/en not_active Expired - Fee Related
- 2013-02-26 US US13/777,513 patent/US9255153B2/en not_active Expired - Fee Related
- 2013-03-13 US US13/798,494 patent/US9238693B2/en not_active Expired - Fee Related
- 2013-08-22 US US13/973,187 patent/US9522957B2/en not_active Expired - Fee Related
-
2016
- 2016-11-08 US US15/345,860 patent/US9932404B2/en not_active Expired - Fee Related
-
2017
- 2017-02-24 SM SM201700127T patent/SMT201700127B/it unknown
- 2017-03-13 HR HRP20170415TT patent/HRP20170415T1/hr unknown
- 2017-03-14 CY CY20171100323T patent/CY1118797T1/el unknown
-
2018
- 2018-02-15 US US15/898,112 patent/US20180179294A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170415T1 (hr) | Antagonisti toll-like receptora 3 | |
| Mishra et al. | Esophageal remodeling develops as a consequence of tissue specific IL-5-induced eosinophilia | |
| US11045434B1 (en) | Niclosamide formulations for treating disease | |
| Sajjan et al. | Elastase-and LPS-exposed mice display altered responses to rhinovirus infection | |
| JP2010500360A (ja) | 炎症性サイトカイン阻害剤による下気道炎症疾患の局所療法 | |
| Kumar et al. | Intranasal IFN-γ gene transfer protects BALB/c mice against respiratory syncytial virus infection | |
| JP5172679B2 (ja) | 呼吸器疾患の治療のためのインターフェロン−λ療法 | |
| JP2000507557A (ja) | ウリジン三リン酸及び関連化合物による線毛ジスキネシアの治療方法 | |
| CN102596227A (zh) | 用于治疗cxcl8介导的肺部炎症的组合物 | |
| KR20230024883A (ko) | 제형 | |
| Contini et al. | A new pharmacological approach based on remdesivir aerosolized administration on SARS-CoV-2 pulmonary inflammation: A possible and rational therapeutic application | |
| Hu et al. | Japonicone A antagonizes the activity of TNF-α by directly targeting this cytokine and selectively disrupting its interaction with TNF receptor-1 | |
| Veerati et al. | Airway mechanical compression: its role in asthma pathogenesis and progression | |
| CA3165957A1 (en) | Methods, compositions, and vaccines for treating a virus infection | |
| Fang et al. | Effectiveness of favipiravir (T-705) against wild-type and oseltamivir-resistant influenza B virus in mice | |
| KR20220164478A (ko) | Il-22 이량체를 사용하는 바이러스-유발 기관 손상 또는 부전의 예방 또는 치료 방법 | |
| WO2022056897A1 (zh) | 白细胞介素37与干扰素联用在治疗病毒感染中的应用 | |
| Bentivegna et al. | The linkage between upper respiratory tract infections and otitis media: evidence of the ‘united airways concept | |
| US20150246095A1 (en) | Methods and pharmaceutical compositions for the prophylactic treatment of bacterial superinfections post-influenza | |
| EP4015634A1 (en) | Sirna and compositions for prophylactic and therapeutic treatment of virus diseases | |
| RU2010114008A (ru) | ТЕРАПЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ ГАСТРИНА 1 И G-Pen-GRGDSPCA | |
| Bozanich et al. | Acute Influenza A infection induces bronchial hyper-responsiveness in mice | |
| Thompson et al. | Otorhinolaryngologic manifestations of eosinophilic esophagitis | |
| Ayoub et al. | Pulmonary aerosolized formulation or nasal drops containing recombinant human angiotensin converting enzyme 2 (rhace2) as a potential therapy against covid-19 | |
| CN113416711A (zh) | 一种sars-cov-2病毒株、小鼠模型的构建方法和应用 |